The Entry of Biosimilars into the US Market
CMR Institute
Course description
The Entry of Biosimilars into the US Market
More biosimilars are expected to enter the US market in the coming years, potentially creating a more competitive market for biologic products and other competitive products. Understanding the basics of biosimilars is crucial for sales teams with products that treat conditions such as rheumatoid arthritis, anemia, inflammatory bowel disease, skin conditions, and some cancers. This module explains how biosimilars are developed and the key concept of interchangeability. It also describes how customers view the emergence of biosimilars, including their expectations for how the products could affect healthcare costs in the US.
Who should attend?
Pharmaceutical sales professionals
Training Content
1. Define what biosimilars are and how they are made.
2. Explain the concept of interchangeability as it relates to biosimilars.
3. Identify some of the key federal and state regulations affecting biosimilars in the US.
4. Describe lessons learned from the introduction of biosimilars in other countries.
5. Explain why customers are interested in biosimilars and how biosimilars could affect the US market.
Costs
Inquire for more information.
About CMR Institute
Through our extensive online blended learning library CMR Institute helps pharmaceutical, medical device and diagnostic professionals maximize market access, connect effectively with decision makers, and demonstrate the value of their products and services. Founded by a team of visionary physicians...
